Search
CCR5 mAb
go.drugbank.com/drugs/DB05906ExperimentalCCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (
OSI-930
go.drugbank.com/drugs/DB05913InvestigationalOSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angio...
LS11
go.drugbank.com/drugs/DB05918InvestigationalLS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.
Dovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with...
Totrombopag
go.drugbank.com/drugs/DB05930InvestigationalSB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. … , thus representing a significant problem in the treatment of cancer patients.
IL-2 pDNA
go.drugbank.com/drugs/DB05935ExperimentalVical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma
Leronlimab
go.drugbank.com/drugs/DB05941InvestigationalLeronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.[L12684] It was first described in the literature in 2001.
MDX-1303
go.drugbank.com/drugs/DB05945InvestigationalMDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal